These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 23726723)

  • 1. Increased medication compliance of liver transplant patients switched from a twice-daily to a once-daily tacrolimus-based immunosuppressive regimen.
    Eberlin M; Otto G; Krämer I
    Transplant Proc; 2013; 45(6):2314-20. PubMed ID: 23726723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring.
    Kuypers DR; Peeters PC; Sennesael JJ; Kianda MN; Vrijens B; Kristanto P; Dobbels F; Vanrenterghem Y; Kanaan N;
    Transplantation; 2013 Jan; 95(2):333-40. PubMed ID: 23263559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of medication adherence with simplified once-daily immunosuppressive regimen in stable kidney transplant recipients: A prospective cohort study.
    Oh CK; Bang JB; Kim SJ; Huh KH; Kim SJ; Jeon JS; Han SY; Cho HR; Kwon YJ; Lee SH; Kim YS
    Asian J Surg; 2020 Jun; 43(6):660-667. PubMed ID: 31353239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment satisfaction in renal transplant patients taking tacrolimus once daily.
    van Boekel GA; Kerkhofs CH; Hilbrands LB
    Clin Ther; 2013 Nov; 35(11):1821-9.e1. PubMed ID: 24135441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of switching from twice-daily to once-daily tacrolimus formulation on quality of life, anxiety, and transplant benefit perception after kidney transplantation.
    Calia R; Lai C; Aceto P; Luciani M; Romagnoli J; Lai S; Gargiulo A; Citterio F
    Transplant Proc; 2011 May; 43(4):1020-3. PubMed ID: 21620041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conversion of twice-daily to once-daily tacrolimus is safe in stable adult living donor liver transplant recipients.
    Kim SH; Lee SD; Kim YK; Park SJ
    Hepatobiliary Pancreat Dis Int; 2015 Aug; 14(4):374-9. PubMed ID: 26256081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased adherence eight months after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation.
    Doesch AO; Mueller S; Akyol C; Erbel C; Frankenstein L; Ruhparwar A; Ehlermann P; Dengler TJ; Katus HA
    Drug Des Devel Ther; 2013; 7():1253-8. PubMed ID: 24174870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A switch from conventional twice-daily tacrolimus to once-daily extended-release tacrolimus in stable kidney transplant recipients.
    Hatakeyama S; Fujita T; Yoneyama T; Yoneyama T; Koie T; Hashimoto Y; Saitoh H; Funyu T; Narumi S; Ohyama C
    Transplant Proc; 2012 Jan; 44(1):121-3. PubMed ID: 22310594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis for optimizing the modified release tacrolimus (Advagraf) after kidney transplantation: A prospective randomized trial.
    Bakr MA; Nagib AM; Donia AF; Denewar AA; Abu-Elmagd MM; Abbas MH; Abdel-Rahman AM; Mashaly ME; Elsaftawy MM; Ghoneim MA
    Saudi J Kidney Dis Transpl; 2018; 29(6):1267-1273. PubMed ID: 30588956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant.
    Papadopoulos-Köhn A; Achterfeld A; Paul A; Canbay A; Timm J; Jochum C; Gerken G; Herzer K
    Transplantation; 2015 Apr; 99(4):841-7. PubMed ID: 25208324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An observational study evaluating tacrolimus dose, exposure, and medication adherence after conversion from twice- to once-daily tacrolimus in liver and kidney transplant recipients.
    Bäckman L; Persson CA
    Ann Transplant; 2014 Mar; 19():138-44. PubMed ID: 24637379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful conversion from twice-daily to once-daily tacrolimus in liver transplantation: observational multicenter study.
    Dopazo C; Rodriguez R; Llado L; Calatayud D; Castells L; Ramos E; Molina V; García R; Fabregat J; Charco R
    Clin Transplant; 2012; 26(1):E32-7. PubMed ID: 21958123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First clinical experience with the new once-daily formulation of tacrolimus.
    First MR
    Ther Drug Monit; 2008 Apr; 30(2):159-66. PubMed ID: 18367975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of modified-release tacrolimus after conversion in liver transplant patients indicates potentially favorable outcomes in selected cohorts.
    Considine A; Tredger JM; Heneghan M; Agarwal K; Samyn M; Heaton ND; O'Grady JG; Aluvihare VR
    Liver Transpl; 2015 Jan; 21(1):29-37. PubMed ID: 25312292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence to and Acceptance of Once-Daily Tacrolimus After Kidney and Liver Transplant: Results From OSIRIS, a French Observational Study.
    Cassuto E; Pageaux GP; Cantarovich D; Rostaing L; Loupy A; Roche B; Duvoux C; Moreau K; Thervet E; Mazouz H; Bourhis Y; Dharancy S; Kessler M;
    Transplantation; 2016 Oct; 100(10):2099-2106. PubMed ID: 27653227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conversion from twice-daily to once-daily tacrolimus administration in liver transplant patient.
    Merli M; Di Menna S; Giusto M; Giannelli V; Lucidi C; Loria I; Ginanni Corradini S; Mennini G; Rossi M
    Transplant Proc; 2010 May; 42(4):1322-4. PubMed ID: 20534292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of a medication adherence enhancing intervention in transplantation: The MAESTRO-Tx trial.
    Dobbels F; De Bleser L; Berben L; Kristanto P; Dupont L; Nevens F; Vanhaecke J; Verleden G; De Geest S
    J Heart Lung Transplant; 2017 May; 36(5):499-508. PubMed ID: 28162931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of conversion from twice-daily tacrolimus (prograf) to once-daily prolonged-release tacrolimus (graceptor) in stable kidney transplant recipients.
    Nakamura Y; Hama K; Katayama H; Soga A; Toraishi T; Yokoyama T; Kihara Y; Jojima Y; Konno O; Iwamoto H; Takeuchi H; Hirano T; Shimazu M
    Transplant Proc; 2012 Jan; 44(1):124-7. PubMed ID: 22310595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Multicenter, Prospective, Observational Study of Conversion from Twice-Daily Immediate-Release to Once-Daily Prolonged-Release Tacrolimus in Liver Transplant Recipients in France: The COBALT Study.
    Dumortier J; Duvoux C; Dubel L; Bazin F; Houssel-Debry P
    Ann Transplant; 2019 Aug; 24():506-516. PubMed ID: 31451681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conversion from twice daily tacrolimus capsules to once daily extended-release tacrolimus (LCP-Tacro): phase 2 trial of stable liver transplant recipients.
    Alloway RR; Eckhoff DE; Washburn WK; Teperman LW
    Liver Transpl; 2014 May; 20(5):564-75. PubMed ID: 24493215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.